Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.39
SPPI's Cash-to-Debt is ranked lower than
74% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. SPPI: 1.39 )
Ranked among companies with meaningful Cash-to-Debt only.
SPPI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2  Med: 8.76 Max: 17918
Current: 1.39
0.2
17918
Equity-to-Asset 0.54
SPPI's Equity-to-Asset is ranked lower than
64% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SPPI: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
SPPI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.57 Max: 0.95
Current: 0.54
0.2
0.95
Piotroski F-Score: 2
Altman Z-Score: 0.14
Beneish M-Score: -1.51
WACC vs ROIC
12.33%
-41.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -58.23
SPPI's Operating Margin % is ranked higher than
58% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. SPPI: -58.23 )
Ranked among companies with meaningful Operating Margin % only.
SPPI' s Operating Margin % Range Over the Past 10 Years
Min: -484.81  Med: -33.57 Max: 30.17
Current: -58.23
-484.81
30.17
Net Margin % -62.39
SPPI's Net Margin % is ranked higher than
56% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. SPPI: -62.39 )
Ranked among companies with meaningful Net Margin % only.
SPPI' s Net Margin % Range Over the Past 10 Years
Min: -443.64  Med: -43.33 Max: 35.19
Current: -62.39
-443.64
35.19
ROE % -35.77
SPPI's ROE % is ranked higher than
54% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. SPPI: -35.77 )
Ranked among companies with meaningful ROE % only.
SPPI' s ROE % Range Over the Past 10 Years
Min: -72  Med: -23.84 Max: 39.19
Current: -35.77
-72
39.19
ROA % -19.45
SPPI's ROA % is ranked higher than
62% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. SPPI: -19.45 )
Ranked among companies with meaningful ROA % only.
SPPI' s ROA % Range Over the Past 10 Years
Min: -61.52  Med: -12.49 Max: 23.98
Current: -19.45
-61.52
23.98
ROC (Joel Greenblatt) % -7236.22
SPPI's ROC (Joel Greenblatt) % is ranked lower than
86% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. SPPI: -7236.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SPPI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9016.53  Med: -1954.97 Max: 3089.46
Current: -7236.22
-9016.53
3089.46
3-Year Revenue Growth Rate -7.80
SPPI's 3-Year Revenue Growth Rate is ranked lower than
65% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. SPPI: -7.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SPPI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.2 Max: 202.1
Current: -7.8
0
202.1
3-Year EBITDA Growth Rate 20.60
SPPI's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SPPI: 20.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SPPI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.9  Med: -17.5 Max: 108.9
Current: 20.6
-70.9
108.9
3-Year EPS without NRI Growth Rate -2.70
SPPI's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SPPI: -2.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SPPI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -70.1  Med: -15.8 Max: 128.1
Current: -2.7
-70.1
128.1
GuruFocus has detected 3 Warning Signs with Spectrum Pharmaceuticals Inc $SPPI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SPPI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SPPI Guru Trades in Q2 2016

Joel Greenblatt 39,070 sh (New)
Paul Tudor Jones 42,767 sh (+257.11%)
Jim Simons 4,558,117 sh (+37.95%)
» More
Q3 2016

SPPI Guru Trades in Q3 2016

Barrow, Hanley, Mewhinney & Strauss 238,988 sh (New)
Paul Tudor Jones 79,444 sh (+85.76%)
Jim Simons 5,541,957 sh (+21.58%)
Joel Greenblatt Sold Out
» More
Q4 2016

SPPI Guru Trades in Q4 2016

Paul Tudor Jones 86,378 sh (+8.73%)
Barrow, Hanley, Mewhinney & Strauss 238,988 sh (unchged)
Jim Simons 5,177,312 sh (-6.58%)
» More
Q1 2017

SPPI Guru Trades in Q1 2017

Jim Simons 5,679,800 sh (+9.71%)
Barrow, Hanley, Mewhinney & Strauss 231,745 sh (-3.03%)
Paul Tudor Jones 21,900 sh (-74.65%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:PGNX, NAS:BCRX, NAS:NTLA, NAS:ASMB, NAS:ITCI, NAS:GERN, NAS:MACK, NAS:ADAP, NAS:BOLD, NAS:IMGN, NAS:NLNK, NAS:ACIU, NAS:ARGX, NAS:ARNA, NAS:ATRA, OTCPK:SXMDF, NAS:CYAD, NAS:AVDL, NAS:PTCT, OTCPK:SPHDF » details
Traded in other countries:NTR.Germany,
Headquarter Location:USA
Spectrum Pharmaceuticals Inc is a biotechnology company with fully integrated commercial and drug development operations with a primary focus on oncology and hematology.

Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history
PB Ratio 2.13
SPPI's PB Ratio is ranked higher than
71% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. SPPI: 2.13 )
Ranked among companies with meaningful PB Ratio only.
SPPI' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.09 Max: 5.24
Current: 2.13
0.64
5.24
PS Ratio 3.33
SPPI's PS Ratio is ranked higher than
79% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. SPPI: 3.33 )
Ranked among companies with meaningful PS Ratio only.
SPPI' s PS Ratio Range Over the Past 10 Years
Min: 1.07  Med: 3.21 Max: 530.91
Current: 3.33
1.07
530.91
Current Ratio 3.44
SPPI's Current Ratio is ranked lower than
58% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. SPPI: 3.44 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.9 Max: 16.82
Current: 3.44
0.56
16.82
Quick Ratio 3.26
SPPI's Quick Ratio is ranked lower than
56% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SPPI: 3.26 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.84 Max: 16.8
Current: 3.26
0.56
16.8
Days Inventory 66.98
SPPI's Days Inventory is ranked higher than
75% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SPPI: 66.98 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 65.64  Med: 98.78 Max: 281.63
Current: 66.98
65.64
281.63
Days Sales Outstanding 109.46
SPPI's Days Sales Outstanding is ranked lower than
71% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. SPPI: 109.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.09  Med: 101.41 Max: 138.24
Current: 109.46
9.09
138.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.90
SPPI's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SPPI: -7.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPPI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -149.9  Med: -23.85 Max: -3.6
Current: -7.9
-149.9
-3.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 41.07
SPPI's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. SPPI: 41.07 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SPPI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.84  Med: 8.88 Max: 279.33
Current: 41.07
0.84
279.33
Price-to-Tangible-Book 11.06
SPPI's Price-to-Tangible-Book is ranked lower than
78% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. SPPI: 11.06 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SPPI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.66  Med: 6.08 Max: 581.43
Current: 11.06
0.66
581.43
Price-to-Intrinsic-Value-Projected-FCF 1.58
SPPI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. SPPI: 1.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SPPI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.09  Med: 1.62 Max: 12.11
Current: 1.58
1.09
12.11
Price-to-Median-PS-Value 1.04
SPPI's Price-to-Median-PS-Value is ranked lower than
51% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SPPI: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SPPI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 2.25 Max: 3541.67
Current: 1.04
0.18
3541.67
Earnings Yield (Greenblatt) % -18.12
SPPI's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. SPPI: -18.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SPPI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.12  Med: 11.6 Max: 1967.3
Current: -18.12
-18.12
1967.3

More Statistics

Revenue (TTM) (Mil) $131.7
EPS (TTM) $ -1.07
Beta1.78
Short Percentage of Float12.13%
52-Week Range $3.21 - 8.00
Shares Outstanding (Mil)80.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 111 105 172
EPS ($) -0.98 -0.58 0.12
EPS without NRI ($) -0.98 -0.58 0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
Goodhaven Funds' First-Quarter Shareholder Letter May 17 2017 
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 

More From Other Websites
Top 4 Small-Cap Stocks for 2017 May 23 2017
Edited Transcript of SPPI earnings conference call or presentation 2-May-17 8:30pm GMT May 19 2017
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017... May 16 2017
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : May 8, 2017 May 08 2017
Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 May 05 2017
Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SPPI-US :... May 05 2017
Why Spectrum Pharmaceuticals Stock Is Sinking Today May 03 2017
Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma May 03 2017
Spectrum Pharma reports 1Q loss May 02 2017
Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update May 02 2017
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : April 27, 2017 Apr 27 2017
Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care... Apr 27 2017
Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast Apr 25 2017
Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum... Apr 21 2017
Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SPPI-US :... Apr 14 2017
Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American... Apr 04 2017
Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate Mar 31 2017
Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ®... Mar 31 2017
Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell... Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)